August 4th Week, 2026 Regulatory Events 🎯 The US FDA has approved Jazz Pharmaceuticals, BeOne Medicines and Zymeworks Inc.' zanidatamab-hrii (Ziihera; biparatopic HER2 BsAb) + fluoropyrimidine- and platinum-containing chemo ± BeOne's tislelizumab-jsgr (Tevimbra; anti-PD-1) for the first-line Tx of adults with HER2+ advanced gastroesophageal adenocarcinoma (GEA) (Ref1) ❓ How is the approval expected to impact the GEA Tx paradigm? 🎯 The EC has approved Gilead Sciences’s

24/07/2025 GenFleet Therapeutics and Verastem Oncology's VS-7375 received the Fast Track Designation from the US FDA for pancreatic cancer (Ref) The US FDA granted the Fast Track Designation to GenFleet Therapeutics and Verastem Oncology's VS-7375 (oral KRAS G12D (ON/OFF) inhibitor) for the first-line treatment of patients with KRAS G12D-mutated locally advanced or metastatic adenocarcinoma of the pancreas, and for the treatment of patients with KRAS G12D-mutated locally adva